Fukano Reiji 深野玲司

… Alternative Names

Reiji Fukano 深野玲司

Less

Researcher Number	00403676
Other IDs
Affiliation (Current)	2026: 産業医科大学, 医学部, 教授
Affiliation (based on the past Project Information) *help	2024: 産業医科大学, 医学部, 教授 2022 – 2023: 山口大学, 大学院医学系研究科, 准教授
Review Section/Research Field	Principal Investigator Basic Section 52050:Embryonic medicine and pediatrics-related
Keywords	Principal Investigator 悪性リンパ腫 / 遺伝子解析 / ALK陽性未分化大細胞リンパ腫 / 微小播種性病変 / 薬剤耐性 / ALK阻害薬 / ALK陽性 / 未分化大細胞リンパ腫

Elucidation of resistance mechanisms to ALK inhibitors and development of novel therapies in ALK-positive anaplastic large cell lymphomaPrincipal Investigator
- Principal Investigator
  
  Reiji Fukano
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 52050:Embryonic medicine and pediatrics-related
- Research Institution
  University of Occupational and Environmental Health, Japan
  Yamaguchi University

All 2025 2024 2023

All Journal Article Presentation

[Journal Article] Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial2024
- Author(s)
  Mori Tetsuya、Osumi Tomoo、Kada Akiko、Ohki Kentaro、Koga Yuhki、Fukano Reiji、Fujita Naoto、Mitsui Tetsuo、Mori Takeshi、Saito Akiko M.、Nakazawa Atsuko、Kobayashi Ryoji、Sekimizu Masahiro
- Journal Title
  
  European Journal of Haematology
  
  Volume: 112 Issue: 4 Pages: 585-593
- DOI
  10.1111/ejh.14148
- URL
  https://marianna-u.repo.nii.ac.jp/records/2001118
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22K07821
[Journal Article] Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Children’s Cancer Group Multicentre Trial, JPLSG B-NHL-20)2024
- Author(s)
  Sekimizu Masahiro、Fukano Reiji、Koga Yuhki、Mitsui Tetsuo、Fujita Naoto、Mori Takeshi、Hori Daiki、Tanaka Makito、Ohki Kentaro、Iwafuchi Hideto、Nakazawa Atsuko、Mori Tetsuya、Kobayashi Ryoji、Hashimoto Hiroya、M. Saito Akiko、Kamei Michi
- Journal Title
  
  BMJ Open
  
  Volume: 14 Issue: 3 Pages: e080762-e080762
- DOI
  10.1136/bmjopen-2023-080762
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K07821, KAKENHI-PROJECT-21K07744
[Journal Article] Prognostic value of minimal disseminated disease assessed using digital polymerase chain reaction for 3'ALK assays in pediatric anaplastic lymphoma kinasepositive anaplastic large cell lymphoma2023
- Author(s)
  Fukano Reiji、Iijima-Yamashita Yuka、Iwafuchi Hideto、Nakazawa Atsuko、Saito Akiko M.、Takimoto Tetsuya、Sekimizu Masahiro、Suehiro Yutaka、Yamasaki Takahiro、Hasegawa Shunji、Mori Tetsuya、Horibe Keizo
- Journal Title
  
  Haematologica
  
  Volume: 109 Issue: 2 Pages: 652-656
- DOI
  10.3324/haematol.2023.282812
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K07821
[Presentation] ALK陽性未分化大細胞リンパ腫のALK阻害薬耐性に関わる原因遺伝子の解明2025
- Author(s)
  齋藤佑介、喜安純一、宮崎幸大、宮村能子、崔日承、頼晋也、林正樹、宇佐美郁哉、盛武浩、白鳥聡一、水上洋一、深野玲司
- Organizer
  第67回日本小児血液・がん学会
- Data Source
  KAKENHI-PROJECT-22K07821

1. 加藤格 (10610454)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
2. 水上洋一 (80274158)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results

Fukano Reiji 深野玲司

Reiji Fukano 深野玲司

Research Projects

Research Products

Co-Researchers

Elucidation of resistance mechanisms to ALK inhibitors and development of novel therapies in ALK-positive anaplastic large cell lymphomaPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Journal Article] Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial2024

Author(s)

Journal Title

DOI

URL

Data Source

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Prognostic value of minimal disseminated disease assessed using digital polymerase chain reaction for 3'ALK assays in pediatric anaplastic lymphoma kinasepositive anaplastic large cell lymphoma2023

Author(s)

Journal Title

DOI

Data Source

[Presentation] ALK陽性未分化大細胞リンパ腫のALK阻害薬耐性に関わる原因遺伝子の解明2025

Author(s)

Organizer

Data Source

Fukano Reiji 深野 玲司

Reiji Fukano 深野 玲司

Research Projects

Research Products

Co-Researchers

Elucidation of resistance mechanisms to ALK inhibitors and development of novel therapies in ALK-positive anaplastic large cell lymphomaPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

[Journal Article] Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial2024

Author(s)

Journal Title

DOI

URL

Data Source

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Prognostic value of minimal disseminated disease assessed using digital polymerase chain reaction for 3'ALK assays in pediatric anaplastic lymphoma kinasepositive anaplastic large cell lymphoma2023

Author(s)

Journal Title

DOI

Data Source

[Presentation] ALK陽性未分化大細胞リンパ腫のALK阻害薬耐性に関わる原因遺伝子の解明2025

Author(s)

Organizer

Data Source

Fukano Reiji 深野玲司

Reiji Fukano 深野玲司